Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)

May 20, 2026 6:49 AM
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Marker Therapeutics (NASDAQ: MRKR).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments